Indeed, the global oncology community trusts ESMO to disseminate the latest results of cancer research. Why? Because it is ...

The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...

But sex health assessments are not yet part of oncological clinical practice, despite studies showing that infertility and ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

ROCKVILLE, Md. and SUZHOU, China, Sept. 13, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical ...

New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with ...

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic ...

Patients with advanced SSC of the anal canal have a marked survival benefit when immunotherapy is added to standard-of-care ...

Belong.Life, a leading global provider of AI-powered patient education and support solutions, announced today that the European Society For Medical Oncology (ESMO) has selected Belong.Life's abstract ...

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...

Congress 2024 will be held in Barcelona, Spain from September 13 to 17, 2024. Sichuan Kelun-Biotech Biopharmaceutical Co., ...